CPT® Code 86829

Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); qualitative assessment of the presence or absence of antibody(ies) to HLA Class I or Class II HLA antigens

The human leukocyte antigen (HLA) system is a critical component of the major histocompatibility complex (MHC), which plays a vital role in the immune system's ability to recognize self from non-self. This system is essential for the identification of specific characteristics of an individual's cells and tissues, thereby enabling the body to defend against foreign substances, including microorganisms and non-self cells and tissues. The HLA system is divided into two main classes: Class I and Class II. The CPT® Code 86829 pertains to the qualitative assessment of antibodies to HLA antigens, specifically focusing on the presence or absence of these antibodies against HLA Class I or Class II antigens. This assessment is crucial in various clinical scenarios, particularly in the context of organ transplantation, where the presence of HLA antibodies can significantly influence the risk of immunological responses. The testing methodology often involves solid phase assays, such as enzyme-linked immunosorbent assay (ELISA), which utilizes fluorescent beads coated with HLA molecules. These beads can be analyzed using flow cytometry or Luminex instrumentation to detect the antibodies. The qualitative nature of this test allows healthcare providers to determine whether a patient has developed antibodies against HLA antigens, which is particularly important for patients previously identified with Class I or Class II HLA antibodies.